Vir Biotechnology Inc (VIR) financials
Vir Biotechnology revenue and earnings by year
Vir Biotechnology's revenue was $68.6 million in the fiscal year to December 31, 2025, down 7.6% from the year before. Net income was -$438 million, -638.9% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 49.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.07 | 0.07 | 0.09 | 1.62 | 1.10 | 0.08 | 0.01 | 0.01 | 0.00 |
| Revenue growth | -7.6% | -13.9% | -94.7% | 47.5% | 1334.4% | 843.9% | -24.2% | 293.9% | — |
| Gross profit | 0.07 | 0.07 | 0.08 | 1.47 | 1.03 | — | — | — | — |
| Gross margin | 100.0% | 98.9% | 96.8% | 90.9% | 94.0% | — | — | — | — |
| Operating income | -0.48 | -0.59 | -0.68 | 0.83 | 0.42 | -0.30 | -0.18 | -0.12 | -0.08 |
| Operating margin | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% | -388.9% | -2199.7% | -1112.6% | -3009.5% |
| Net income | -0.44 | -0.52 | -0.62 | 0.52 | 0.53 | -0.30 | -0.17 | -0.12 | -0.07 |
| Net margin | -638.9% | -703.4% | -713.7% | 31.9% | 48.3% | -391.1% | -2159.0% | -1086.3% | -2579.5% |
| Diluted EPS | -$3.16 | -$3.83 | -$4.59 | $3.83 | $3.96 | -$2.48 | — | — | — |
| Free cash flow | -0.40 | -0.45 | -0.80 | 1.60 | -0.07 | -0.20 | -0.14 | -0.10 | -0.07 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open VIR in Markets.
How Vir Biotechnology makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| License & Collaboration Revenue | $239M | 100.0% |
| Grant | $11.0K | 0.0% |
See also: VIR returns
No forecast, no recommendation. This page describes Vir Biotechnology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.